Name: Latest research reports of Laurus Labs Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Laurus Labs Ltd.

NSE: LAURUSLABS | BSE: 540222 | ISIN: INE947Q01028 | Industry: Pharmaceuticals
| Expensive Star

617.8000 -2.75 (-0.44%)

NSE May 05, 2025 15:31 PM

60.28% Gain from 52W Low

Volume: 1.7M

Laurus Labs Ltd.

27 Jan 2025

617.80

-0.44%

Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E

Sell: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps

Laurus Labs Ltd. has gained 38.10% in the last 1 Year